Cerebrospinal fluid and plasma free amino acid levels in multilple sclerosis
Multipl sklerozun (MS) patofizyolojisiyle bazı peptidler ve aminoasitlerin ilişkili olduğu öne sürülmüştür. Dolayısıyla, beyin omurilik sıvısı (BOS) ve plazma amino asit (a.a) düzeylerini MS hastalarında ve sağlıklı bireylerde incelemeyi ve iki grubu karşılaştırmayı amaçladık. 10 MS hastası ile 10 sağlıklı birey çalışmaya alındı. Plazma ve BOS a.a düzeyleri Pickering post kolon derivatizasyon HPLC yöntemiyle tayin edildi. BOS için, total, esansiyel, glukoketojenik, standart ve türev a.a miktarları MS ve kontrol grupları arasında anlamlı farklılık göstermezken, nonesansiyel (p
Multipl sklerozda beyin omirilik sıvısı ve plazma serbest aminoasit düzeyleri
Some peptides and excitatory amino acids are claimed to be involved in the pathophysiology of multiple sclerosis (MS). Thus, we aimed to investigate cerebrospinal fluid (CSF) and plasma amino acid (a.a.) levels in MS patients and healthy subjects and to compare the two groups of subjects in terms of a.a content of CSF and plasma. Ten MS patients and 10 healthy subjects were included in this study. Plasma and CSF a.a. levels were determined by HPLC method with Pickering post-column derivatization. For CSF, while there was no significant difference between MS and control groups in terms of total, essential, glucoketogenic, standard and derivated a.a. contents, nonessential (p<0.05) and glucogenic (p<0.05) a.a. contents were found higher in the patients. For plasma, while no significant difference was present with respect to essential, glucoketogenic and derivated a.a. contents, total (p<0.001), nonessential (p<0.001), glucogenic (p<0.001) and standard (p<0.001) a.a. contentswere found increased in MS patients. Plasma/CSF a.a. ratios were 1.51 and 1.99 in the control and MS groups, respectively. MS patients had significantly higher CSF Thr, Gln, Tyr and Phe and plasma Thr, Ser, Gln, and Gly levels, and plasma/CSF a.a. ratio when compared to healthy controls.
1. Raine CS, Traugott U Immunopathology of the lesion in multiple sclerosis and chronic relapsing experimental allergic encephalomyelitis. Immunoregulatory processes in experimental allergic encephalomyelitis and multiple sclerosis. In: Vandenpark AA, Paus Jem, eds. Elsevier, Amsterdam: pp: 151-212, 1984. 2. Waksman BH (1985) Mechanisms in multiple sclerosis. Nature (Lond.) 318: 104- 105. 3. Piek J., Boldt-Götth A., Wieczorek D. and Bock W.J Cerebrospinal fluid free amino acids in patients with spinal space- occupying lesions. A preliminary report 1: Acta Neurochir (Wien) 78 (1-2): 43- 455, 1985. 4. Heiblim DL, Evans HE., Glass L and Agbayani MM Child Neurology: Amino acid concentrations in cerebrospinal fluid. Arch Neurol 35: 765-68, 1978. 5. Klivenyi P., Kekesi K., Juhasz G and Vecsei L Amino acid concentrations in cerebrospinal fluid of patients with multiple sclerosis. Acta Neurol Scand 95: 96-98, 1997. 6. Spink DC, Swann JW., Snead OC, Waniewski RA and Martin DL1 Analysis of aspartate and glutamate in human cerebrospinal fluid by high-performance liquid chromatography with automated precolumn derivatization. Anal Biochem 158: 79-86, 1986.
7. Weitz R-, Merlob P., Amir J and Reisner SH A possible role for aspartic acid in neonatal seizures. Arch Neurol 38(4): 258-59, 1981. 8. Pickering Laboratories, Inc User's Manual Amino Acids. 1951 Colony Street, Suite S Mountain View, CA 94043 USA. 1998. 9. Baig S., Halawa I and Qureshi GA High- performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolities in cerebrospinal fluid from patients with neurological disorders. Biomed Chromatogr5: 108-112, 1991. 10. Poser CM., Paty DW., Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Guidelines for research protocols. Ann Neurol 13: 227-231, 1983. 11. Link H and Tibbling G Principle of albumin and lgG in neurological disorders. 2. Relation of the concentration of the proteins in serum and the CSF. Scand J Clin Lab Invest 37: 391-395, 1977. >. 12. Pickering Laboratories, Inc Product Catolog No 2 HPLC Post-column Derivatization Instruments, Columns, Methods, Chemicals, Reagents 1951 Colony Street, Suite S Mountain View, CA 94043 USA. Pp; 55. 1997. 13. Merrill JE Proinflammatory and antiinflammatory cytokines in multiple sclerosis and central nervous system acquired immundeficiency syndrome. J Immunother 12: 167-70, 1992. 14. Vecsei L., Csala B., Widerlov E., Ekman R and Palffy G Lumbar cerebrospinal fluid concentrations of somatostatin and neuropeptide Y in multiple sclerosis. Brain Res Bull 25: 411-13, 1990. 15. Burnashev N., Khodorova A., Jonas P et al. Calcium-permeable AMPA-kainate receptors in fusiform cerebellar glial cell. Science 256: 1566-70, 1992. 16. Qureshi GA. and Baig MS Quantification of free amino acids in biological samples by high performance liquid chromatography. Application of the method in evaluating amino acid levels in cerebrospinal fluid and plasma of patients with multiple sclerosis. J ChromatogrA 459: 237-244, 1988.
17. Monaco F., Fumero S., Mondino A and Mutani R Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative Diseases. Neurol Neurosurg Psychiat 42(7): 640-601, 1979. 18. Westall FC, Hawkin A., Ellison GM and Myers LW Abnormal glutamate metabolism in multiple sclerosis. J Neurol Sci 47(3): 353-364, 1980. 19. Oldenford WH and Szabo J Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol 230(1): 94-8, 1976. 20. Pardridge WM. and Oldenford WH Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 401(1): 128-36, 1975. 21. Humoller FL, Mahler OJ annd Parker MM Distrubition of amino acids between plasma and spinal fluid. Int J Neuropsych 2: 293- 97,1966.